PCVX vs TECH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PCVX · Vaxcyte$63.89 ▲ 3.18%
TECH · Bio-Techne$72.78 ▲ 0.17%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PCVX +48.9%
- TECH +27.4%
Head to head
| Metric | PCVX | TECH |
|---|---|---|
| Price | $63.89 | $72.78 |
| Change today | ▲ 3.18% | ▲ 0.17% |
| Market cap | $10.11B | $11.43B |
| Return, 3 months | +9.6% | +1.0% |
| Return, year to date | +38.5% | +24.3% |
| Return, 1 year | +53.4% | +27.5% |
| P/E (TTM) | – | 62.7 |
| P/B | 4.1 | 5.4 |
| P/E percentile vs own 5y | 88th | 50th |
| Dividend yield | – | 0.44% |
| Revenue growth (YoY, latest qtr) | – | +1.3% |
| Net profit growth (YoY) | -70.7% | +409.0% |
| Gross margin | – | 65.8% |
| Operating margin | – | 22.4% |
| Net margin | – | 15.0% |
| Return on equity | -36.5% | 9.0% |
| Analyst target vs. price | +92.1% | +0.3% |
| Analyst buy share | 88% | 0% |
| RSI (14) | 53 | 61 |
| 30-day volatility | 100.2% | 1.9% |
| Max drawdown, 1 year | -28.0% | -39.3% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TECH is the largest of the group by market value.
- PCVX has returned the most over the past year.
- TECH has been the calmest stock over the last 30 days.